JBCHEPHARM - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.8
| Stock Code | JBCHEPHARM | Market Cap | 33,353 Cr. | Current Price | 2,082 ₹ | High / Low | 2,195 ₹ |
| Stock P/E | 45.9 | Book Value | 238 ₹ | Dividend Yield | 0.74 % | ROCE | 25.9 % |
| ROE | 20.2 % | Face Value | 1.00 ₹ | DMA 50 | 2,007 ₹ | DMA 200 | 1,874 ₹ |
| Chg in FII Hold | 1.45 % | Chg in DII Hold | -1.97 % | PAT Qtr | 179 Cr. | PAT Prev Qtr | 200 Cr. |
| RSI | 60.9 | MACD | 7.97 | Volume | 2,54,194 | Avg Vol 1Wk | 2,40,866 |
| Low price | 1,495 ₹ | High price | 2,195 ₹ | PEG Ratio | 1.93 | Debt to equity | 0.01 |
| 52w Index | 83.9 % | Qtr Profit Var | 14.6 % | EPS | 46.5 ₹ | Industry PE | 30.2 |
📊 JB Chemicals & Pharmaceuticals (JBCHEPHARM) shows moderate potential for swing trading. The RSI at 60.9 indicates healthy momentum, while the MACD (7.97) is positive, reflecting bullish signals. The current price (₹2,082) is above both the 50 DMA (₹2,007) and 200 DMA (₹1,874), showing strong technical support. Fundamentals are solid with ROCE (25.9%) and ROE (20.2%), but the high P/E (45.9) compared to industry PE (30.2) and PEG ratio (1.93) suggest stretched valuations. Sequential PAT decline (₹200 Cr. → ₹179 Cr.) is a concern.
💡 Optimal Entry Price: Around ₹2,000–₹2,050, near 50 DMA support.
📈 Exit Strategy (if already holding): Consider booking profits near ₹2,150–₹2,190, close to the recent high.
✅ Positive
- Strong ROCE (25.9%) and ROE (20.2%) highlight efficiency.
- Price trading above both 50 DMA and 200 DMA shows technical strength.
- Low debt-to-equity ratio (0.01) ensures financial stability.
- Dividend yield of 0.74% provides steady returns.
⚠️ Limitation
- High P/E ratio (45.9) compared to industry PE (30.2), suggesting overvaluation.
- PEG ratio of 1.93 indicates expensive growth expectations.
- Sequential PAT decline from ₹200 Cr. to ₹179 Cr.
📉 Company Negative News
- PAT declined sequentially, showing weaker earnings momentum.
- DII holdings decreased (-1.97%), reflecting reduced domestic investor confidence.
📈 Company Positive News
- Quarterly profit variation shows 14.6% YoY growth.
- FII holdings increased (+1.45%), signaling foreign investor support.
- EPS of ₹46.5 reflects strong earnings power.
🏭 Industry
- Industry PE at 30.2 vs. JBCHEPHARM’s PE of 45.9 highlights premium valuation.
- Pharmaceutical sector remains resilient with long-term demand drivers.
🔎 Conclusion
JBCHEPHARM is technically strong and fundamentally stable, but valuations are stretched. Swing traders may enter near ₹2,000–₹2,050, targeting exits around ₹2,150–₹2,190. While earnings growth is modest, strong sector outlook and investor support make it a cautious but viable swing trade candidate.